Unlocking the Promise of Biology
Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel solid tumor cancer therapies.View Our Academic Collaborations
Two Late-Stage Therapeutics for Multiple Oncology Indications with Unmet Medical Needs
VAL-083 is a structurally-unique small molecule targeting DNA to inhibit cancer cell replication and cell division, which leads to cell death. Like other established agents extensively studied by U.S. National Cancer Institute (NCI), such as cisplatin, paclitaxel and camptothecin, VAL-083 has been assessed in over 40 Phase I and Phase II clinical trials sponsored by the NCI.
REM-001 is a second-generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds.